ClinicalTrials.gg
RecruitingNCT06442566ACTIONUpdated Nov 5, 2026

ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain

A Phase 1/2 interventional study of Buprenorphine Patch and Placebo in Opioid Withdrawal and Chronic Pain, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Medical University of South Carolina · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 5, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing buprenorphine in Chronic Pain — 1 open to participants now, 1 under way, none of them phase 3. Buprenorphine · Chronic Pain.

Planned enrollment
10th of 22
240 · median 207
Started
2024
the only one that year
Phase 1/2
Only one
of the 22
Registered
22nd of 22
by date
Lead sponsor
1 of 22
Medical University of South Carolina

Among the 22 studies testing buprenorphine in Chronic Pain, this one is the 10th largest by planned enrollment, is the only one that started in 2024, is the only one in phase 1/2, and was the 22nd registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

1 of the 22 studies testing buprenorphine in Chronic Pain is open now, in 1 country.

By country, each count listing its studies:

About buprenorphine

Buprenorphine: first FDA approval 1981 (BUPRENEX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing buprenorphine in Chronic Pain, or all of them as a file.
02

Study summary

This study will sequentially evaluate three novel and scalable interventions for at-risk individuals on long term opioid therapy for chronic pain: (1) low-dose transdermal buprenorphine initiation without a period of opioid withdrawal; (2) a brief Cognitive Behavioral Intervention for pain (CBI); and (3) "accelerated" rTMS over the left dorsolateral prefrontal cortex, by examining standardized repeated measures of clinical outcomes at baseline, during treatment, and at 4-, 12-, 24- and 52-week follow-up.

Read the detailed description

With little evidence available to guide the provision of clinical care for patients on long-term opioid therapy (LTOT) in whom the risks outweigh the benefits, major questions remain about optimizing the risk/benefit profile of LTOT, including: how to best engage patients voluntarily in this process; the safety, tolerability and effectiveness of newer treatment approaches; and optimal treatment selection. The primary objective of the proposed study is to begin to systematically address gaps in this important area to improve pain, reduce risk, and improve quality of life for individuals on LTOT.

03

Conditions studied

  • Opioid Withdrawal
  • Chronic Pain

Browse trials for

Keywords

  • opioids
  • chronic pain
  • TMS
  • long-term opioid use
  • buprenorphine
  • transcranial magnetic stimulation
04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age >/= 18 years

English-speaking

On LTOT, defined as taking prescription opioid therapy for 90 days or more

Past week average morphine equivalent dose (MED) >/= 20mg

Willing and able to complete written

Willing and able to use a mobile/cell phone

Have at least one additional risk for opioid toxicity or overdose from the following list:

Opioid Toxicity or Overdose Risks:

  1. Taking benzodiazepines with opioids
  2. Substance Use Disorder diagnosis [non-tobacco; Opioid Risk Tool]

2) Having ever experienced an overdose 4) Current major medical problem [e.g. mod-severe liver disease, pancreatitis, chronic pulmonary disease, untreated sleep apnea, hospitalized for an acute medical issue in the past 6 months]a,b 5) Response to BPI Item 8 \<30%, suggesting less than moderately response to pain treatmentc 6) Co-morbid psychiatric diagnosis [Opioid Risk Tool] 7) Signs of opioid misuse [any score >0 on the following COMM Items: 3,4,5,9,10,11,14,15,16] 8)Opioid Risk Tool >3 or Current Opioid Misuse Measure ≥ 9 9) Struggling with any of the following side effects from opioids [self-report]

  1. Dizziness and/or falls
  2. Difficult-to-manage stomach pain, nausea, constipation or GI issues
  3. Fatigue or low energy
  4. Sleepiness or sedation
  5. Trouble with memory or thinking clearly [COMM Item 1>0]
  6. Other troublesome side effect [open answer]

Exclusion criteria

Exclusion criteria:

Known allergy to buprenorphine

Active moderate or severe substance use disorder with the exception of those listed below:

  1. . Those with nicotine use disorder.
  2. . Those meeting criteria for prescription opioid use disorder using only prescribed opioids will be considered on a case-by-case basis.

Cognitive disorder limiting ability to consent or fully participate in the brief cognitive intervention

Receiving methadone or buprenorphine treatment for OUD or pain

Taking naltrexone

Pregnancy

Currently incarcerated

Taking medications that prolong , as determined by study investigators

Personal/immediate family history of Long QT Syndrome.

Significant or unstable condition/s or treatments that may impact safe participation in the study (as determined by the study investigators) such as significant cardiac condition (e.g. poorly-controlled heart failure, current or past cardiac arrhythmia, sustained systolic blood pressure >180), significant metabolic disorder (e.g. labile diabetes, significant electrolyte abnormality), cancer (e.g. brain cancer, chemotherapy-induced cognitive impairment), major psychiatric disorder (e.g. active bipolar disorder, schizophrenia spectrum or other psychotic disorder, suicidal/homicidal intent within the past month, or any suicide attempts within the past year or current active suicidal ideation, as determined by medical clinician), developmental disorder (e.g. autism spectrum disorder, intellectual disability), or other neurologic disease (e.g. movement disorder, multiple sclerosis, moderate to severe brain injury).

Enrolled in a clinical trial or has received an medication or device in the last 30 days.

TMS (e.g., ferromagnetic implants, conditions or treatments that lower seizure threshold, taking contraindicated medications, no identifiable motor threshold, as determined by study investigators).

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    open label BUP

    Drug: Buprenorphine Patch

  • Active comparator
    Real vs Placebo BUP

    Drug: Buprenorphine Patch · Drug: Placebo

  • Active comparator
    Real vs Sham TMS

    Device: Transcranial Magnetic Stimulation (TMS) · Device: Sham Transcranial Magnetic Stimulation (TMS)

Interventions

  • DrugBuprenorphineStudies of BuprenorphineBuprenorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Buprenorphine patch dosing will be individualized based on each participant's current morphine-equivalent dose (per package insert/recommendations; between 5mcg and 20mcg per hour). Dosage based on baseline MEQ (\<30 MEQ = 5mcg/hr patch, 30-80 MEQ =10-15mcg/hour patch; \>80 MEQ = 20mcg/hour patch), which will remain on for 7 days (Phase Ia Days 1-7), as tolerated

  • DrugPlacebo

    double-blinded randomization to placebo or transdermal buprenorphine

  • DeviceTranscranial Magnetic Stimulation (TMS)

    double-blinded randomization to REAL intermittent theta burst (iTBS) rTMS

  • DeviceSham Transcranial Magnetic Stimulation (TMS)

    double-blinded randomization to SHAM intermittent theta burst (iTBS) rTMS

06

What researchers measure

Primary outcomes

  1. Intervention Tolerability

    (a) Tolerability of open-label transdermal buprenorphine, defined as the proportion of eligible patients who do not discontinue buprenorphine due to adverse effects, preference, or intolerance. (b) Tolerability of TMS/sham, defined as tolerating 10 sessions of accelerated rTMS

    Time frame: up to Day-13

  2. Pain Severity

    Pain severity is measured by the Brief Pain Inventory (BPI) Severity Scale and is typically scored as the mean of the four severity items ("average," "worst," "least," "now," range 0-10) with a higher score being worse. This outcome will be measured after both the buprenorphine vs. placebo trial and the TMS vs. sham trial.

    Time frame: up to Day-20

Secondary outcomes

  1. Buprenorphine Transition Rate

    Buprenorphine transition rate defined as the proportion of participants who spontaneously elect to continue buprenorphine after Phase I.

    Time frame: Day-20

  2. Quality of Life

    Patient-Reported Outcomes Measurement Information System (PROMIS)-Preference (PROPr) score summarizes multiple domains into a single score anchored at 0 (as bad as dead) and 1 (perfect or ideal health). This score quantifies the value that individuals place on different states of health. PROPr is calculated from the scores for the 7 PROMIS domains: Cognition, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Ability to Participate in Social Roles and Activities. This outcome will be measured after both the buprenorphine vs. placebo trial and the TMS vs. sham trial.

    Time frame: up to Day-20

  3. Pain Interference

    BPI Interference Scale (lowest score 0, highest 40; higher worse)

    Time frame: up to Day-20

  4. Pain Catastrophizing

    Pain Catastrophizing Scale SF 6 (lowest score 0, highest score 24; higher worse)

    Time frame: up to Day-20

  5. Patient Global Impression of Change

    range 1-7, higher worse

    Time frame: up to Day-20

  6. Opioid misuse risk

    Current opioid Misuse Measure (COMM

    Time frame: up to Day-20

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Mar 2028, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 4, 2024
StartActual
Aug 12, 2024
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedOn LTOT, defined as taking daily prescription opioid therapy for 90 days or more
Nov 5, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedBuprenorphineIntervention TolerabilityTime frame: up to Day-13
  • EditedPain Severity -with Buprenorphine PatchTime frame: up to Day-20
Nov 5, 2026
Secondary outcomes
1 edited, 4 added
What changed in the outcomes
  • EditedQuality of Life -with Buprenorphine PatchTime frame: up to Day-20
  • AddedPain InterferenceTime frame: up to Day-20
  • AddedPain CatastrophizingTime frame: up to Day-20
  • AddedPatient Global Impression of ChangeTime frame: up to Day-20
  • AddedOpioid misuse riskTime frame: up to Day-20
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedOn LTOT, defined as taking daily prescription opioid therapy for 90 days or more
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedBuprenorphineIntervention TolerabilityTime frame: up to Day-13
    • EditedPain Severity -with Buprenorphine PatchTime frame: up to Day-20
    Secondary outcomes 1 edited, 4 added
    What changed in the outcomes
    • EditedQuality of Life -with Buprenorphine PatchTime frame: up to Day-20
    • AddedPain InterferenceTime frame: up to Day-20
    • AddedPain CatastrophizingTime frame: up to Day-20
    • AddedPatient Global Impression of ChangeTime frame: up to Day-20
    • AddedOpioid misuse riskTime frame: up to Day-20
    + 3 other changes: verification date, responsible party and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06442566
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Aug 12, 2024
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

Kelly Barth
Contact
stephen@musc.edu
843-792-0686
Rafael Mendoza
Contact
mendozra@musc.edu
Kelly Barth
principal investigator · Medical University of South Carolina

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Buprenorphine

Start the discussion